Journal of Antimicrobial Chemotherapy

(The H4-Index of Journal of Antimicrobial Chemotherapy is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-11-01 to 2023-11-01.)
ResFinder 4.0 for predictions of phenotypes from genotypes1273
COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression352
COVID-19 and the potential long-term impact on antimicrobial resistance212
Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder210
Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey161
Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9139
Evolution of hypervirulence in carbapenem-resistant Klebsiella pneumoniae in China: a multicentre, molecular epidemiological analysis113
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study100
Systematic review of mutations associated with resistance to the new and repurposedMycobacterium tuberculosisdrugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid99
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis92
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-1984
The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community84
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial82
Safety of high-dose ivermectin: a systematic review and meta-analysis82
Favipiravir, an antiviral for COVID-19?76
Implications of antibiotics use during the COVID-19 pandemic: present and future75
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey73
The EUCAST rapid disc diffusion method for antimicrobial susceptibility testing directly from positive blood culture bottles73
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia72
EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories71
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study70
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-1969
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola viru66
An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London66
Identification of the novel tigecycline resistance gene tet(X6) and its variants in Myroides, Acinetobacter and Proteus of food animal origin63
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomize60
A novel tigecycline resistance gene, tet(X6), on an SXT/R391 integrative and conjugative element in a Proteus genomospecies 6 isolate of retail meat origin56
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials55
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study52
Large-scale assessment of antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review52
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-1950
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries49
Lopinavir pharmacokinetics in COVID-19 patients49
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital49
In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015–17)47
Faecal carriage, risk factors, acquisition and persistence of ESBL-producing Enterobacteriaceae in dogs and cats and co-carriage with humans belonging to the same household47
Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Moni46
Linezolid resistance in Enterococcus faecium and Enterococcus faecalis from hospitalized patients in Ireland: high prevalence of the MDR genes optrA and poxtA in isolates with diverse genetic backgrou44
Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study41
The changing epidemiology of carbapenemase-producingKlebsiella pneumoniaein Italy: toward polyclonal evolution with emergence of high-risk lineages41
Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia41